Healthy adults
Conditions
Interventions
Ingestion of the test food (5 packages/day) to the subjects for 4 weeks.
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy subjects ranging in age from 20 to 64, at the moment of giving informed consent to take part in this research. (2) Subjects who can give informed consent to participate in this research after being provided with an explanation of our experimental protocol detail.
Exclusion criteria
Exclusion criteria: (1) Subjects who take steadily in the health-specific/functional/supplementary/health foods, and will have any difficulty in giving up taking them after the consent. (2) Subjects who have taken some kind of medicine, and have any difficulty in refraining from taking them during this research. (3) Subjects with excessive alcohol intake. (4) Subjects with current and/or previous medical history of serious diseases in heart, liver, kidney and/or digestive organs. (5) Pregnant, possibly pregnant women during this research, or lactating ones. (6) Subjects with drug and/or food allergy. (7) Subjects who are now under other clinical researches with some kind of medicine/food, or participated in those within four weeks before this research, or planning to join those after the consent. (8) Subjects who donated over 200 mL of their blood and/or blood components within a month to this research. (9) Males who donated their whole blood (400 mL) within the last three months to this research. (10) Females who donated their whole blood (400 mL) within the last four months to this research. (11) Males who will be collected in total of their blood (1200 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this research. (12) Females who will be collected in total of their blood (800 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this research. (13) Others who have been determined as ineligible for participation in this research, according to the principal/sub investigator's opinions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of some kind of adverse event and/or side effect. Changes in clinical examination values. | — |
Countries
Japan
Contacts
Public ContactMasanori Numa
CPCC Company Limited Clinical Planning Department
Outcome results
None listed